NPPB and heart failure: Compared to placebo, patients taking valsartan demonstrated an improvement in left ventricular ejection fraction, improved survival at 12 months and decreased NT-proBNP level.27 Given the advances in optimal medical therapy in heart failure, monitoring the left ventricular ejection fraction as well as other complementary variables could form the basis of observational research in real world settings.